Selected research
Industry Growth & Trends
Global Treatments for Alpha-1 Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Treatments for Alpha-1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Treatments for Alpha-1 market include Takeda, Teva Pharmaceutical Industries, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, ProMetic Life Sciences and Kedrion Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Treatments for Alpha-1 market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Treatments for Alpha-1 market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Treatments for Alpha-1 market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Treatments for Alpha-1.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Treatments for Alpha-1 market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Treatments for Alpha-1 Market by Company
Takeda
Teva Pharmaceutical Industries
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
ProMetic Life Sciences
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Treatments for Alpha-1 Segment by Type
Augmentation Therapy
Diabetes
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Treatments for Alpha-1 Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Treatments for Alpha-1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatments for Alpha-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treatments for Alpha-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatments for Alpha-1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Treatments for Alpha-1 companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Augmentation Therapy
- Diabetes
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
Applications
- Hospitals
- Specialty Clinics
- Pharmacies
Companies covered
- Takeda
- Teva Pharmaceutical Industries
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- ProMetic Life Sciences
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Treatments for Alpha-1 Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Treatments for Alpha-1 Market Size by Region (2021-2032)
- 1.4.1 Global Treatments for Alpha-1 Market Size by Region (2021-2026)
- 1.4.2 Global Treatments for Alpha-1 Market Size by Region (2027-2032)
- 1.5 Key Regions Treatments for Alpha-1 Market Size (2021-2032)
- 1.5.1 North America Treatments for Alpha-1 Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Treatments for Alpha-1 Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Treatments for Alpha-1 Market Size Growth Rate (2021-2032)
- 1.5.4 South America Treatments for Alpha-1 Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Treatments for Alpha-1 Market Size Growth Rate (2021-2032)
2 Treatments for Alpha-1 Market by Type
- 2.1 Type Introduction
- 2.1.1 Augmentation Therapy
- 2.1.2 Diabetes
- 2.1.3 Cystic Fibrosis(CF)
- 2.1.4 Non-CF Bronchiectasis(NCFB)
- 2.1.5 Other
- 2.2 Global Treatments for Alpha-1 Market Size by Type
- 2.2.1 Global Treatments for Alpha-1 Market Size Overview by Type (2021-2032)
- 2.2.2 Global Treatments for Alpha-1 Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Treatments for Alpha-1 Market Size Forecasted by Type (2027-2032)
- 2.3 Global Treatments for Alpha-1 Market Size by Regions
- 2.3.1 North America Treatments for Alpha-1 Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Treatments for Alpha-1 Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Treatments for Alpha-1 Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Treatments for Alpha-1 Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Treatments for Alpha-1 Market Size Breakdown by Type (2021-2026)
3 Treatments for Alpha-1 Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Specialty Clinics
- 3.1.3 Pharmacies
- 3.2 Global Treatments for Alpha-1 Market Size by Application
- 3.2.1 Global Treatments for Alpha-1 Market Size Overview by Application (2021-2032)
- 3.2.2 Global Treatments for Alpha-1 Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Treatments for Alpha-1 Market Size Forecasted by Application (2027-2032)
- 3.3 Global Treatments for Alpha-1 Market Size by Regions
- 3.3.1 North America Treatments for Alpha-1 Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Treatments for Alpha-1 Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Treatments for Alpha-1 Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Treatments for Alpha-1 Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Treatments for Alpha-1 Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Treatments for Alpha-1 Industry Trends
- 4.2 Treatments for Alpha-1 Industry Drivers
- 4.3 Treatments for Alpha-1 Industry Opportunities and Challenges
- 4.4 Treatments for Alpha-1 Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Treatments for Alpha-1 Revenue (2021-2026)
- 5.2 Global Treatments for Alpha-1 Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Treatments for Alpha-1 Key Company Headquarters & Area Served
- 5.4 Global Treatments for Alpha-1 Company, Product Type & Application
- 5.5 Global Treatments for Alpha-1 Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Treatments for Alpha-1 Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Treatments for Alpha-1 Players Market Share by Revenue in 2025
- 5.6.3 2025 Treatments for Alpha-1 Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Takeda Treatments for Alpha-1 Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Teva Pharmaceutical Industries
- 6.2.1 Teva Pharmaceutical Industries Company Information
- 6.2.2 Teva Pharmaceutical Industries Business Overview
- 6.2.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio
- 6.2.5 Teva Pharmaceutical Industries Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pfizer Treatments for Alpha-1 Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 GlaxoSmithKline Treatments for Alpha-1 Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 Baxter
- 6.5.1 Baxter Company Information
- 6.5.2 Baxter Business Overview
- 6.5.3 Baxter Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Baxter Treatments for Alpha-1 Product Portfolio
- 6.5.5 Baxter Recent Developments
- 6.6 AstraZeneca
- 6.6.1 AstraZeneca Company Information
- 6.6.2 AstraZeneca Business Overview
- 6.6.3 AstraZeneca Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 AstraZeneca Treatments for Alpha-1 Product Portfolio
- 6.6.5 AstraZeneca Recent Developments
- 6.7 Vertex Pharmaceuticals
- 6.7.1 Vertex Pharmaceuticals Company Information
- 6.7.2 Vertex Pharmaceuticals Business Overview
- 6.7.3 Vertex Pharmaceuticals Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 6.7.5 Vertex Pharmaceuticals Recent Developments
- 6.8 ProMetic Life Sciences
- 6.8.1 ProMetic Life Sciences Company Information
- 6.8.2 ProMetic Life Sciences Business Overview
- 6.8.3 ProMetic Life Sciences Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio
- 6.8.5 ProMetic Life Sciences Recent Developments
- 6.9 Kedrion Group
- 6.9.1 Kedrion Group Company Information
- 6.9.2 Kedrion Group Business Overview
- 6.9.3 Kedrion Group Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Kedrion Group Treatments for Alpha-1 Product Portfolio
- 6.9.5 Kedrion Group Recent Developments
- 6.10 Kamada Ltd
- 6.10.1 Kamada Ltd Company Information
- 6.10.2 Kamada Ltd Business Overview
- 6.10.3 Kamada Ltd Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Kamada Ltd Treatments for Alpha-1 Product Portfolio
- 6.10.5 Kamada Ltd Recent Developments
- 6.11 Grifols
- 6.11.1 Grifols Company Information
- 6.11.2 Grifols Business Overview
- 6.11.3 Grifols Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Grifols Treatments for Alpha-1 Product Portfolio
- 6.11.5 Grifols Recent Developments
- 6.12 CSL Behring
- 6.12.1 CSL Behring Company Information
- 6.12.2 CSL Behring Business Overview
- 6.12.3 CSL Behring Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 CSL Behring Treatments for Alpha-1 Product Portfolio
- 6.12.5 CSL Behring Recent Developments
- 6.13 Chiesi Pharmaceuticals
- 6.13.1 Chiesi Pharmaceuticals Company Information
- 6.13.2 Chiesi Pharmaceuticals Business Overview
- 6.13.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio
- 6.13.5 Chiesi Pharmaceuticals Recent Developments
- 6.14 Boehringer Ingelheim
- 6.14.1 Boehringer Ingelheim Company Information
- 6.14.2 Boehringer Ingelheim Business Overview
- 6.14.3 Boehringer Ingelheim Treatments for Alpha-1 Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio
- 6.14.5 Boehringer Ingelheim Recent Developments
7 North America
- 7.1 North America Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Treatments for Alpha-1 Market Size by Country (2021-2026)
- 7.3 North America Treatments for Alpha-1 Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Treatments for Alpha-1 Market Size by Country (2021-2026)
- 8.3 Europe Treatments for Alpha-1 Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Treatments for Alpha-1 Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Treatments for Alpha-1 Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Treatments for Alpha-1 Market Size by Country (2021-2026)
- 10.3 South America Treatments for Alpha-1 Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Treatments for Alpha-1 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Treatments for Alpha-1 Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst